鲁索替尼乳膏(Ruxolitinib cream)价格一览

As an outstanding representative of Janus kinase (JAK) inhibitors, ruxolitinib cream not only brings new treatment hope to patients with chronic skin diseases, but also triggers extensive discussions about the economic burden due to its high price of the original drug and the emergence of generic drug options.

Prices Overview of Original Drugs and Generic Drugs

As an original manufacturer, Incyte, an American company, produces 60-gram products that are priced at a high price in the market, with each box selling for about $10,800. This price reflects the huge investment in R&D, production and patent protection of the original drug.

With the expiration of patents and the continuous maturation of generic drug technology, Bangladesh Yaopin International and other companies have launched a generic version of ruxolitinib cream, with a specification of 30 grams and a price of only $400 per box. This price advantage enables more patients to afford treatment and improves drug accessibility.

Ruxolitinib CreamVitiligo TreatmentClinical Trial

Trial scale and design: In the field of vitiligo treatment, Ruxolitinib Cream has shown encouraging efficacy. Two global, randomized, double-blind, placebo-controlled Phase 3 clinical trials, TRuE-V1 and TruE-V2, recruited more than 600 adolescent and adult patients (age >12 years old) with vitiligo, providing solid data support for evaluating the safety and efficacy of ruxolitinib cream.

Significant short-term efficacy: Clinical trial results show that after 24 weeks of treatment with ruxolitinib cream, patients improved vitiligo severity index (such as skin lesion area, color change, etc.) significantly better than patients who received placebo treatment. In particular, 21% of patients who used the 1.5% concentration cream twice a day achieved the goal of 75% or more improvement in skin lesions at week 24, reflecting the short-term efficacy advantage of ruxolitinib cream.

Long-term efficacy and persistence: In order to explore the long-term efficacy of ruxolitinib cream, the study extended the treatment cycle to the 52nd week. The results showed that 52.6% of patients in the ruxolitinib cream group achieved a 75% or greater improvement in the Facial Vitiligo Area Score Index (F-VASI), which was much higher than the placebo group. Notably, even among patients who switched from placebo to ruxolitinib cream, a significant proportion of patients met F-VASI75 improvement criteria at 52 weeks, further demonstrating the sustained efficacy of ruxolitinib cream.

F-VASI90 achievement rate: More significantly, between weeks 24 and 52, among patients who continued to use ruxolitinib cream, the proportion of patients who achieved F-VASI90 (i.e. 90% improvement in condition) increased from 15.3% to 32.9%, while in the placebo switching group, this proportion increased from 2.2% to 12.2%. This data not only highlights the excellent long-term efficacy of ruxolitinib cream, but also shows that it can still maintain good therapeutic effects after a period of discontinuation, providing patients with continued confidence and hope in treatment.